CEL-SCI Corporation Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by CEL-SCI Corporation (CEL-SCI) on July 26, 2024, with the report date reflecting the earliest event of July 26, 2024. The filing details the entry into a Material Definitive Agreement for a capital raise and the subsequent closing of the offering on July 29, 2024.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of common stock and pre-funded warrants.
- Securities Issued: 3,715,000 shares of common stock at $1.00 per share and pre-funded warrants to purchase up to 7,130,000 shares at $0.99 per warrant.
- Gross Proceeds: $10,845,000 (inclusive of pre-funded warrant exercise prices).
- Placement Agent Fees: 7.0% of gross proceeds plus expense reimbursement up to $165,000.
- Use of Proceeds: Funding continued development of Multikine, general corporate purposes, and working capital.
- Financial Metrics: The filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the reporting period.
Material Changes and Agreements
The primary material change is the execution of a Placement Agency Agreement with ThinkEquity LLC. Key terms include:
- Lock-Up Period: The Company agreed not to issue or announce the issuance of additional common stock or convertible securities for 90 days from July 26, 2024.
- Insider Lock-Up: Directors and officers agreed to a 90-day lock-up period on their existing holdings.
- Warrant Terms: Pre-funded warrants are immediately exercisable at $0.01 per share and expire upon full exercise.
Outlook, Risks, and Management Commentary
Management intends to utilize the net proceeds to advance the development of Multikine. The filing includes standard forward-looking statements cautioning that actual results may differ materially from projections. Risks and uncertainties are referenced in the Company's prospectus supplement filed on February 9, 2024, and its Annual Report on Form 10-K for the fiscal year ended September 30, 2023. No specific new risks or contingencies were detailed in this 8-K beyond the standard disclaimers.
Investor Verification Checklist
- Verify the final net proceeds after deducting the 7.0% placement fee and the $165,000 expense cap.
- Confirm the dilution impact of the 3,715,000 new shares and the potential 7,130,000 shares from pre-funded warrants.
- Review the full text of the Placement Agency Agreement (Exhibit 1.1) for specific termination provisions and indemnification obligations.
- Check the Company's latest 10-K and prospectus supplement for updated risk factors regarding the Multikine development program.